Preliminary melanoma plans

  • 09:35

Immunicum announced preliminary plans to conduct two separate studies with INTUVAX for the treatment of advanced melanoma in… Read more

Outcome Rights Issue

  • 10:37

Immunicum’s rights issue of approximately SEK 111 million, which ended on June 14, 2016, was oversubscribed. In view… Read more

Application to main market

  • 13:58

Immunicum applies for listing on the Nasdaq Stockholm main market. Read the press release here: Press release 160502 –… Read more


  • 09:47

In the exercise period for the warrants in Immunicum’s option program for senior executives that ended March 31,… Read more

Rights issue

  • 09:28

Immunicum announces fully underwritten rights issue of about SEK 111 million to extend phase II-trial with new clinics… Read more